American Society of Hematology

Figure 3.

In silico validation of the MetSig. (A) PFS and OS of the 469 patients treated with R-CHOP chemoimmunotherapy in the Sha et al34 data set according to the T-GEP–based MetSig showing significant differences in outcome between MetSig-low and MetSig-high patients. (B) Forest plot depicting multivariable analyses for PFS in the Sha et al34 data set. (C) OS of the 233 patients treated with R-CHOP chemoimmunotherapy in the Lenz et al35 data set according to the MetSig status. (D) Forest plot depicting multivariate analyses for OS (Lenz et al35 data set).

In silico validation of the MetSig. (A) PFS and OS of the 469 patients treated with R-CHOP chemoimmunotherapy in the Sha et al³⁴ data set according to the T-GEP–based MetSig showing significant differences in outcome between MetSig-low and MetSig-high patients. (B) Forest plot depicting multivariable analyses for PFS in the Sha et al³⁴ data set. (C) OS of the 233 patients treated with R-CHOP chemoimmunotherapy in the Lenz et al³⁵ data set according to the MetSig status. (D) Forest plot depicting multivariate analyses for OS (Lenz et al³⁵ data set).

This Feature Is Available To Subscribers Only